STAT3 and acute myeloid leukemia: Though niclosamide has been reported to target several signaling pathways including Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch [20, 23–25, 34, 40], the mechanism of action of niclosamide in AML has not been extensively studied.